New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
09:10 EDTQCOR, AGIO, PFE, MNKD, AEO, MAT, P, VOCS, MNK, WWEOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
News For QCOR;MNK;VOCS;P;MAT;AEO;MNKD;PFE;AGIO;WWE From The Last 14 Days
Check below for free stories on QCOR;MNK;VOCS;P;MAT;AEO;MNKD;PFE;AGIO;WWE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 20, 2014
11:21 EDTAEOAmerican Eagle says search for new CEO 'underway'
Subscribe for More Information
10:31 EDTAEOAmerican Eagle rallies after earnings beat, levels to watch
Subscribe for More Information
08:05 EDTAEOAmerican Eagle sees Q3 EPS ex-items 17c-19c, consensus 18c
08:05 EDTAEOAmerican Eagle sees FY14 CapEx $230M
Subscribe for More Information
08:04 EDTAEOAmerican Eagle reports Q2 EPS 3c, consensus 0c
Reports Q2 revenue $710.6M, consensus $689.94M. Reports Q2 SSS down 7%.
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
06:01 EDTAEOAmerican Eagle implied volatility of 52 at upper end of index mean range
Subscribe for More Information
August 19, 2014
15:16 EDTAEONotable companies reporting before tomorrow's open
Subscribe for More Information
14:43 EDTAEOAmerican Eagle September 11 straddle priced for 12.3% move into Q2
11:53 EDTAEOAeropostale soars as Geiger returns as CEO
Subscribe for More Information
11:18 EDTAEOStocks with call strike movement; AEO TSLA
American Eagle (AEO) February 14 call option implied volatility decreased 2% to 39, Tesla (TSLA) December 285 call option implied volatility decreased 3% to 39 according to IVolatility.
10:42 EDTMNKDOptions with decreasing implied volatility
Subscribe for More Information
10:28 EDTAEOHigh option volume stocks
Subscribe for More Information
09:51 EDTPPandora calls activate on renewed speculation of an activist investor
Pandora August weekly 27.5 and 29 calls are active on total call volume of 5K contracts (1K puts) on renewed speculation of an activist investor. August weekly call option implied volatility is at 77, September is at 58 and December is at 55; compared to its 26-week average of 55 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:44 EDTPRumor: Pandora moves up on renewed speculation of an activist investor
Subscribe for More Information
09:21 EDTMNKMallinckrodt now a component of the S&P 500 Index
The inclusion comes following the completion of Mallinckrodt’s acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company’s balance sheet, cash generation and leverage position.
05:48 EDTAEOStocks with implied volatility movement; AEO YHOO
Subscribe for More Information
August 18, 2014
11:41 EDTPFECubist rises after report sparks takeover interest speculation
Subscribe for More Information
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTPFECambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use